要闻！核电板块强势拉升 久盛电气涨停领跑

核电板块强势拉升 久盛电气涨停领跑

北京 - 6月13日上午，A股市场三大指数震荡回升，其中，核电板块表现强势，多个股涨停。久盛电气(002038)涨停，涨幅20.00%；长城电工(601006)涨停，涨幅20.00%；中广核技(000881)涨停，涨幅20.00%；东方钽业(000672)涨停，涨幅20.00%；多普乐(300036)涨停，涨幅20.00%；中国广核(000880)涨幅9.99%。

**消息面来看，多重利好因素刺激了核电板块。**首先，国家发改委近日发布了《关于促进核电高质量发展的意见》，提出要加快推进核电发展，构建清洁低碳、安全高效的核电体系。这表明国家对核电发展的支持力度进一步加大，将为核电行业带来新的发展机遇。

**其次，近期国际能源价格持续高企，也为核电的发展提供了有利条件。**核电作为清洁低碳的能源，在应对气候变化和能源安全方面具有重要作用。在国际能源价格高企的背景下，核电的经济性和环保优势更加凸显，发展核电有利于降低能源成本，保障能源安全。

**分析人士认为，在多重利好因素的推动下，核电板块有望持续走强。**看好核电板块后市发展，建议投资者关注相关上市公司。

以下是一些具体的投资建议：

• **关注具有技术优势和良好业绩的核电设备制造商。**这类公司在核电发展中将直接受益。
• **关注核电运营商。**随着核电装机容量的不断增长，核电运营商的盈利能力也将稳步提升。
• **关注核电产业链上下游企业。**核电产业链涉及的企业众多，包括铀矿开采、核燃料加工、核电站建设、核废料处理等。投资者可以根据自身的投资风险偏好选择合适的投资标的。

**免责声明：**本文仅供参考，不构成投资建议。投资者在做出投资决策前应谨慎考虑自身的风险承受能力。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.